Cite this: *Chem. Commun.*, 2015, 51, 14617

Received 7th July 2015,
Accepted 12th August 2015

DOI: 10.1039/c5cc05571g

www.rsc.org/chemcomm

Jadomycins, put a bigger ring in it: isolation of seven- to ten-membered ring analogues†

Camilo F. Martinez-Farina^a and David L. Jakeman^{*b}

We report the production, isolation, and characterization of jadomycins with seven-, nine-, and ten-membered E-rings, all of which are unique natural product ring scaffolds. This significantly expands the scope of a non-enzymatic biosynthetic step in jadomycin biosynthesis in order to produce novel natural products.

Natural products have traditionally been obtained from a variety of sources, including plants, fungi, and bacteria.^{1,2} Bacteria have long been prolific sources of novel natural products, with the Actinomycete genus *Streptomyces* being responsible for approximately 32% of all bioactive metabolites.^{3,4} The discovery of novel natural products is important both medically, through the discovery of new clinically active metabolites, and chemically, through the discovery of new chemical scaffolds. This is the case with *Streptomyces venezuelae* ISP5230, which has been shown to produce baduretin,⁵ chloramphenicol⁶ and the jadomycins,^{7,8} a family of secondary metabolites. From the initial discovery of jadomycin A⁸ and the glycosylated jadomycin B,⁹ over twenty-five jadomycins have been isolated.^{10,11} This has been accomplished through the exploitation of a unique non-enzymatic step in the type II polyketide synthase (PKS) biosynthetic pathway (Scheme 1),^{12–14} leading to the expansion of the jadomycin library through the incorporation of differing amino acids¹⁰ and subsequent chemical derivatization of chemoselective handles.^{15,16}

A novel eight-membered ring-containing jadomycin, was recently observed preferentially over the predicted five-membered oxazolone ring species.¹⁵ In order to investigate this further, growths using 4-aminobutanoic acid, 6-aminohexanoic acid, 7-aminoheptanoic acid, and 8-aminooctanoic acid were conducted. These, along with glycine,¹⁰ β -alanine,¹⁰ and 5-aminopentanoic acid,¹⁵ would complete a series of increasing, non-substituted

jadomycin E-rings from the five-membered oxazolone ring to the eleven-membered ring jadomycin and would be novel natural product scaffolds.

All amino acids investigated allowed for the growth of *S. venezuelae* ISP5230 VS1099, as determined by OD₆₀₀ (Fig. 1). However, not all appeared to produce jadomycins, as determined by Abs₅₂₆ values (Fig. 1). At 48 hours, a typical jadomycin production period, it appeared that production favoured the smaller ring size, with cultures containing 4-aminobutanoic acid having the highest Abs₅₂₆ values and those with 8-aminooctanoic acid having the lowest Abs₅₂₆ values. Due to their low Abs₅₂₆ readings, productions using 6-aminohexanoic acid, 7-aminoheptanoic acid, and 8-aminooctanoic acid were grown for 150 h. At this time-point, only cultures containing 8-aminooctanoic acid failed to produce any appreciable absorbance, suggesting an inability to produce the corresponding jadomycin.

Scheme 1 Jadomycin biosynthetic pathway where R is an amino acid side chain and R¹ is a proton¹³ or a carboxylate group¹⁴ and structures of ring-expanded variants described herein (R is L-digitoxose).

^a Department of Chemistry, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada

^b College of Pharmacy, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada. E-mail: david.jakeman@dal.ca

† Electronic supplementary information (ESI) available: Experimental procedures, supporting figures, NMR spectra, and characterization data are described. See DOI: 10.1039/c5cc05571g

Fig. 1 Monitoring the cell growth (OD_{600}) and the production of coloured compounds (Abs_{526}) in the presence of 4-aminobutanoic acid (●), 5-aminopentanoic acid (■), 6-aminohexanoic acid (▲), 7-aminoheptanoic acid (▼), and 8-amino-octanoic acid (◆). Error bars correspond to standard deviation between triplicates.

Following an initial phenyl column all jadomycin analogues were present by HPLC and LC-MS/MS, with the exception of jadomycin 8-amino-octanoic acid. A series of chromatographic steps afforded the final natural products (Table 1 and Fig. 2); jadomycin Hep (1, 21 mg L⁻¹), jadomycin Non (2, 10 mg L⁻¹), and jadomycin Dec (3, 3 mg L⁻¹). The amounts isolated and Abs_{526} values correlate, and are similar to those of previously isolated jadomycins.^{14,15} The seven-membered ring jadomycin is formed more readily than the eight- or nine-membered ring systems, and the ten-membered ring-containing jadomycin was isolated in the lowest quantity. All jadomycins were isolated as diastereomeric mixtures, arising from the configuration of H3a. Previously, other jadomycins have shown interconversion between the diastereomers, and for this reason, separation of the diastereomers was not attempted.¹⁷

NMR spectroscopy was used to fully characterize the three jadomycin analogues 1–3. ¹H–¹H COSY NMR established the connectivity of the typical jadomycin spin systems; the A ring, D ring, and sugar ring (Fig. 3A). ¹H–¹³C HMBC NMR established the remaining typical jadomycin connectivity by correlating H1'' to C12, H9 to C8, H11 to C13, and H3a to C13a. These correlations are similar to those of recently isolated jadomycins.^{15,18} COSY NMR was also used to identify the presence of the linear amino acids within the jadomycin scaffold (Fig. 3A). HMBC NMR and ROESY NMR were also used to confirm the incorporation of the linear amino acids by correlating H3a to the carbon closest to the nitrogen in the E-ring and H3a to the protons closest to the nitrogen in the E-ring (Fig. 3B). The ¹H-NMR chemical shifts of the seven-membered ring of 1 were also similar to those of synthetic 3-tosyl[1,3]oxazepan-7-one,¹⁹ providing further evidence

Fig. 2 (A) HPLC traces of compounds 1–3. (B) LC-MS/MS fragmentation of compounds 1–3, showing $[M + H]^+$, cleavage of the sugar $[M + H\text{-}digitoxose]^+$, and the cleavage of the amino acid groups to phenanthro-viridin (m/z 306).

Fig. 3 Structural characterization of jadomycin analogues 1–3 showing (A) key COSY NMR correlations (bold) and (B) key HMBC NMR correlations (solid arrow) and key ROESY NMR correlations (dashed arrow) confirming the incorporation of the amino acids into the proposed structures.

Table 1 Diastereomeric ratio, isolated yields, HRMS m/z , and calculated mass for isolated jadomycin analogues

Product	Mj : Mn ^a	Yield (mg L ⁻¹)	HRMS	Calculated mass
1	100 : 67	21	544.1601	544.1578 ^b
Jad AVA ^c	100 : 63	10	558.1753	558.1735 ^b
2	100 : 67	10	572.1887	572.1891 ^b
3	100 : 58 ^d	3	564.2228	564.2228 ^e

^a Major (Mj) and minor (Mn) H3a diastereomeric ratios were determined by ¹H-NMR spectroscopy. ^b HRMS values obtained and calculated are $[M + Na]^+$. ^c *J. Am. Chem. Soc.* 2015, **137**, 3271–3275. ^d Diastereomeric ratio was hard to determine due to signal overlap in the ¹H-NMR spectrum. ^e HRMS values obtained and calculated are $[M + H]^+$.

to confirm the proposed chemical structure. Collectively, the spectroscopic data demonstrate the isolation of jadomycin analogues containing seven-, nine-, and ten-membered E-rings.

While characterizing the isolated jadomycin analogues, it was noted that the H3a chemical shift in CD₃OD changed from the five- (5.18 ppm),⁹ six- (5.53 ppm, CDCl₃),⁹ seven- (5.64 ppm), eight- (5.64 ppm),¹⁴ and nine-membered (5.62 ppm) ring analogues to 4.72 ppm of the ten-membered ring analogue (Fig. 4). This chemical shift is in contrast to previously isolated jadomycins that all have H3a chemical shifts at approximately 5.6 ppm.^{9,14,15} In addition, the H1 (the protons adjacent to the

Fig. 4 Overlaid ROESY spectra of compounds **1–3** and NOESY spectrum of jadomycin AVA showing the irradiation of H3a and subsequent correlations observed.

E-ring carbonyl group) chemical shift changed from the seven- (2.29 ppm), eight- (2.19 ppm),¹⁴ and nine-membered (2.24 ppm) ring analogues to 3.44 ppm in the ten-membered ring analogue. Structural changes were also observed through NOESY/ROESY NMR spectroscopy, where irradiation of H3a showed correlations to protons within the eight-, nine-, and ten-membered rings, other than that of the protons adjacent to the nitrogen (Fig. 4), providing evidence of flexibility in the larger ring structures. These correlations were not observed in the ROESY NMR spectrum of the smaller seven-membered ring analogue (Fig. 4). The combination of chemical shift changes and NOE differences provide a rationale for the 30 nm change in the λ_{max} observed between jadomycin Hep (**1**, 524 nm), jadomycin AVA (522 nm), and jadomycin Non (**2**, 522 nm) as compared to jadomycin Dec (**3**, 551 nm). This is consistent with the change in colour that was observed for the ten-membered jadomycin analogue.

The newly isolated jadomycin analogues **1–3**, together with jadomycin AVA, enables the effect of increasing the size and lipophilicity of the jadomycin E-ring on the biological activity. These data are being collected in collaboration with the National Cancer Institute (USA) and will be reported in due course.

The production and isolation of compounds **1–3** are the first examples of jadomycin analogues incorporating seven-, nine-, and

ten-membered ring structures. These compounds demonstrate new opportunities for non-enzymatic incorporation with linear amino acids of differing chain lengths. Whilst the process of amino acid incorporation is non-enzymatic, the fact that incorporation of 8-aminooctanoic acid was unsuccessful in producing the jadomycin of interest suggests that there are additional factors that determine the scope of reactivity. Investigations into the production of the eleven-membered ring analogue through the use of modified production conditions are being explored, and, if successful, will be reported in due course.

We acknowledge that this research was funded in part by NSERC, CIHR, and NSHRF. We would like to thank Dr Nadine Merkley and Ian Burton at the NRC-IMB for their NMR support and Xiao Feng for acquisition of HRMS data.

Notes and references

- 1 A. L. Harvey, R. Edrada-Ebel and R. J. Quinn, *Nat. Rev. Drug Discovery*, 2015, **15**, 111.
- 2 P. J. Rutledge and G. L. Challis, *Nat. Rev. Microbiol.*, 2015, **13**, 509.
- 3 J. Berdy, *J. Antibiot.*, 2005, **58**, 1.
- 4 K. Scherlach and C. Hertweck, *Org. Biomol. Chem.*, 2009, **7**, 1753.
- 5 J. D. Sidda, L. Song, V. Poon, M. Al-Bassam, O. Lazos, M. J. Buttner, G. L. Challis and C. Corre, *Chem. Sci.*, 2014, **5**, 86.
- 6 J. He, N. Magarvey, M. Piraece and L. C. Vining, *Microbiology*, 2001, **147**, 2817.
- 7 D. L. Jakeman, C. L. Graham, W. Young and L. C. Vining, *J. Ind. Microbiol. Biotechnol.*, 2006, **33**, 767.
- 8 S. W. Ayer, A. G. McInnes, P. Thibault, L. Wang, J. L. Doull, T. Parnell and L. C. Vining, *Tetrahedron Lett.*, 1991, **32**, 6301.
- 9 J. L. Doull, S. W. Ayer, A. K. Singh and P. Thibault, *J. Antibiot.*, 1993, **46**, 869.
- 10 C. N. Borissow, C. L. Graham, R. T. Syvitski, T. R. Reid, J. Blay and D. L. Jakeman, *ChemBioChem*, 2007, **8**, 1198.
- 11 D. L. Jakeman, C. N. Borissow, T. R. Reid, C. L. Graham, S. C. Timmons and R. T. Syvitski, *Chem. Commun.*, 2006, 3738.
- 12 U. Rix, J. Zheng, L. L. Remsing Rix, L. Greenwell, K. Yang and J. Rohr, *J. Am. Chem. Soc.*, 2004, **126**, 4496.
- 13 M. Shan, E. U. Sharif and G. A. O'Doherty, *Angew. Chem., Int. Ed.*, 2010, **49**, 9492.
- 14 M. K. Kharel and J. Rohr, *Curr. Opin. Chem. Biol.*, 2012, **16**, 150.
- 15 A. W. Robertson, C. Martinez-Farina, D. A. Smithen, H. Yin, S. Monroe, A. Thompson, S. A. McFarland, R. T. Syvitski and D. L. Jakeman, *J. Am. Chem. Soc.*, 2015, **137**, 3271.
- 16 S. N. Dupuis, A. W. Robertson, T. Veinot, S. M. A. Monroe, S. E. Douglas, R. T. Syvitski, K. B. Goralski, S. A. McFarland and D. L. Jakeman, *Chem. Sci.*, 2012, **3**, 1640.
- 17 R. T. Syvitski, C. N. Borissow, C. L. Graham and D. L. Jakeman, *Org. Lett.*, 2006, **8**, 697.
- 18 C. F. Martinez-Farina, A. W. Robertson, H. Yin, S. M. A. Monroe, S. A. McFarland, R. T. Syvitski and D. L. Jakeman, *J. Nat. Prod.*, 2015, **78**, 1208.
- 19 M. Chang, S. Wang and C. Pai, *Tetrahedron Lett.*, 2006, **47**, 6389.